131 related articles for article (PubMed ID: 29974729)
1. Effect on prostatic specific antigen by a short time treatment with a Curcuma extract: A real life experience and implications for prostate biopsy.
Fabiani A; Morosetti C; Filosa A; Principi E; Lepri L; Maurelli V; Fioretti F; Servi L
Arch Ital Urol Androl; 2018 Jun; 90(2):107-111. PubMed ID: 29974729
[TBL] [Abstract][Full Text] [Related]
2. [Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy].
Rodríguez-Patrón Rodríguez R; Mayayo Dehesa T; González Galán A; Zuccarino AL; García González R; Cuesta Roca C
Arch Esp Urol; 2002 Dec; 55(10):225-34. PubMed ID: 12611220
[TBL] [Abstract][Full Text] [Related]
3. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
[TBL] [Abstract][Full Text] [Related]
4. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
5. [Examination for indication of systematic biopsy for diagnosis of prostate cancer].
Muraoka K; Takahashi C; Yamamoto Y; Watanabe T; Hirakawa S; Miyagawa I
Nihon Hinyokika Gakkai Zasshi; 1999 Jul; 90(7):657-62. PubMed ID: 10481471
[TBL] [Abstract][Full Text] [Related]
6. Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy?
Remzi M; Dobrovits M; Reissigl A; Ravery V; Waldert M; Wiunig C; Fong YK; Djavan B;
Eur Urol; 2004 Oct; 46(4):451-6. PubMed ID: 15363559
[TBL] [Abstract][Full Text] [Related]
7. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels.
Roehrborn CG; Pickens GJ; Sanders JS
Urology; 1996 Mar; 47(3):347-52. PubMed ID: 8633400
[TBL] [Abstract][Full Text] [Related]
9. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
10. [Prospective validation of a nomogram predictive of a positive initial prostate biopsy].
Ramírez-Backhaus M; Bahilo P; Arlandis S; Santamaría Navarro C; Pontones Moreno JL; Jiménez-Cruz F
Actas Urol Esp; 2010 Jan; 34(1):35-42. PubMed ID: 20223131
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
12. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
Lai WJ; Wang HK; Liu HT; Park BK; Shen SH; Lin TP; Chung HJ; Huang YH; Chang YH
J Chin Med Assoc; 2016 Nov; 79(11):618-624. PubMed ID: 27567440
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
15. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Bretton PR; Evans WP; Borden JD; Castellanos RD
Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
[TBL] [Abstract][Full Text] [Related]
16. Concomitant transrectal ultrasound-guided biopsy and transurethral resection of prostate in patients with urinary retention and elevated serum prostate-specific antigen levels.
Yang TY; Chow YC; Lin WR; Ko MC; Chen M; Chang HK; Hsu JM; Yang S; Lin WC; Chiu AW
J Chin Med Assoc; 2016 Nov; 79(11):605-608. PubMed ID: 27344217
[TBL] [Abstract][Full Text] [Related]
17. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
19. [Echo-guided transrectal biopsy. An analysis of the results in a series of 1900 patients].
Mayayo Dehesa T; Rodríguez-Patrón R; Zuccarino AL; Arias Funez F; Carrera Puerta C; García González R
Arch Esp Urol; 1999 Jun; 52(5):453-63. PubMed ID: 10427883
[TBL] [Abstract][Full Text] [Related]
20. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
